Literature DB >> 33797701

Activation of AMPK inhibits Galectin-3-induced pulmonary artery smooth muscle cells proliferation by upregulating hippo signaling effector YAP.

Qianqian Zhang1, Wenge Li2, Yanting Zhu3, Qingting Wang1, Cui Zhai1, Wenhua Shi1, Wei Feng1, Jian Wang1, Xin Yan1, Limin Chai1, Yuqian Chen1, Cong Li1, Pengtao Liu1, Manxiang Li4.   

Abstract

Galectin-3(Gal-3) is an effective regulator in the pathological process of pulmonary arterial hypertension (PAH). However, the detailed mechanisms underlying Gal-3 contribution to PAH are not yet entirely clear. The aim of the present study was to explore these issues. Proliferation of rat pulmonary arterial smooth muscle cells (PASMCs) was determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Small interfering RNA (siRNA) was applied to silence the expression of yes-associated protein (YAP) and Forkhead box M1 (FOXM1). The protein expression and phosphorylation were measured by immunoblotting. The subcellular location of YAP was determined using immunoblotting and immunofluorescence. Gal-3-stimulated PASMCs proliferation in a time- and dose-dependent manner, this was accompanied with, YAP upregulation, dephosphorylation, and nucleus translocation. Gal-3 further increased FOXM1 and cyclinD1 expression via YAP activation. Interfering YAP/FOXM1 axis suppressed Gal-3-induced PASMCs proliferation. Activation of AMPK also inhibited Gal-3-triggered cells proliferation by targeting YAP/FOXM1/cyclinD1 pathway. Gal-3 induced PASMCs proliferation by regulating YAP/FOXM1/cyclinD1 signaling cascade, and activation of AMPK targeted on this axis and suppressed Gal-3-stimulated PASMCs proliferation. Our study provides novel therapeutic targets for prevention and treatment of PAH.

Entities:  

Keywords:  Galectin-3; Hippo signaling pathway; Pulmonary arterial hypertension; Yes-associated protein

Year:  2021        PMID: 33797701     DOI: 10.1007/s11010-021-04131-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  50 in total

1.  Decreased expression of galectin-3 is associated with progression of human breast cancer.

Authors:  V Castronovo; F A Van Den Brûle; P Jackers; N Clausse; F T Liu; C Gillet; M E Sobel
Journal:  J Pathol       Date:  1996-05       Impact factor: 7.996

2.  [Pulmonary arterial hypertension: epidemiology and registries].

Authors:  Michael D McGoon; Raymond L Benza; Pilar Escribano-Subias; Xin Jiang; Dave P Miller; Andrew J Peacock; Joanna Pepke-Zaba; Tomas Pulido; Stuart Rich; Stephan Rosenkranz; Samy Suissa; Marc Humbert
Journal:  Turk Kardiyol Dern Ars       Date:  2014-10

Review 3.  Galectin-3: mediator of microglia responses in injured brain.

Authors:  Reza Rahimian; Louis-Charles Béland; Jasna Kriz
Journal:  Drug Discov Today       Date:  2017-11-10       Impact factor: 7.851

4.  Galectin-3 modulates carbohydrate-dependent thymocyte interactions with the thymic microenvironment.

Authors:  Déa Maria Serra Villa-Verde; Elizangela Silva-Monteiro; Míriam G Jasiulionis; Désio Aurélio Farias-De-Oliveira; Ricardo Renzo Brentani; Wilson Savino; Roger Chammas
Journal:  Eur J Immunol       Date:  2002-05       Impact factor: 5.532

5.  Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension.

Authors:  Laurent Calvier; Ekaterina Legchenko; Lena Grimm; Hannes Sallmon; Adam Hatch; Brian D Plouffe; Christoph Schroeder; Johann Bauersachs; Shashi K Murthy; Georg Hansmann
Journal:  Heart       Date:  2016-03       Impact factor: 5.994

6.  Decreased galectin-3 expression in prostate cancer.

Authors:  R A Pacis; M J Pilat; K J Pienta; K Wojno; A Raz; V Hogan; C R Cooper
Journal:  Prostate       Date:  2000-07-01       Impact factor: 4.104

Review 7.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

Review 8.  Galectin-3: an open-ended story.

Authors:  Jerka Dumic; Sanja Dabelic; Mirna Flögel
Journal:  Biochim Biophys Acta       Date:  2006-01-18

Review 9.  Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Authors:  Rui Dong; Min Zhang; Qunying Hu; Shan Zheng; Andrew Soh; Yijie Zheng; Hui Yuan
Journal:  Int J Mol Med       Date:  2017-12-05       Impact factor: 4.101

Review 10.  Mechanisms of disease: pulmonary arterial hypertension.

Authors:  Ralph T Schermuly; Hossein A Ghofrani; Martin R Wilkins; Friedrich Grimminger
Journal:  Nat Rev Cardiol       Date:  2011-06-21       Impact factor: 32.419

View more
  4 in total

1.  Activation of Autophagy Induces Monocrotaline-Induced Pulmonary Arterial Hypertension by FOXM1-Mediated FAK Phosphorylation.

Authors:  Cui Zhai; Nana Zhang; Jian Wang; Meng Cao; Jing Luan; Huan Liu; Qianqian Zhang; Yanting Zhu; Yuxin Xue; Shaojun Li
Journal:  Lung       Date:  2022-09-15       Impact factor: 3.777

Review 2.  Phosphodiesterase-4 Inhibitor Roflumilast-Mediated Protective Effect in Sepsis-Induced Late-Phase Event of Acute Kidney Injury: A Narrative Review.

Authors:  Imran Kazmi; Fahad A Al-Abbasi; Muhammad Afzal; Muhammad Shahid Nadeem; Hisham N Altayb; Gaurav Gupta
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-20

3.  Effects of the peripheral CB1 receptor antagonist JD5037 in mono- and polytherapy with the AMPK activator metformin in a monocrotaline-induced rat model of pulmonary hypertension.

Authors:  Patryk Remiszewski; Anna Pędzińska-Betiuk; Krzysztof Mińczuk; Eberhard Schlicker; Justyna Klimek; Janusz Dzięcioł; Barbara Malinowska
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

4.  RAS protein activator like 2 promotes the proliferation and migration of pulmonary artery smooth muscle cell through AKT/mammalian target of Rapamycin complex 1 pathway in pulmonary hypertension.

Authors:  Sheng Hu; Youguang Zhao; Chenming Qiu; Ying Li
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.